1. Home
  2. FCO vs XLO Comparison

FCO vs XLO Comparison

Compare FCO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Global Income Fund Inc.

FCO

abrdn Global Income Fund Inc.

HOLD

Current Price

$3.10

Market Cap

39.4M

Sector

Finance

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$0.55

Market Cap

41.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCO
XLO
Founded
1991
2016
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.4M
41.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FCO
XLO
Price
$3.10
$0.55
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$2.00
AVG Volume (30 Days)
100.1K
480.4K
Earning Date
01-01-0001
03-10-2026
Dividend Yield
14.96%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
N/A
$31,804,000.00
Revenue This Year
N/A
$626.78
Revenue Next Year
N/A
$79.08
P/E Ratio
$12.30
N/A
Revenue Growth
N/A
588.40
52 Week Low
$4.73
$0.53
52 Week High
$6.63
$1.70

Technical Indicators

Market Signals
Indicator
FCO
XLO
Relative Strength Index (RSI) 57.92 27.57
Support Level $3.11 $0.53
Resistance Level $3.26 $0.63
Average True Range (ATR) 0.09 0.03
MACD 0.00 -0.01
Stochastic Oscillator 50.91 16.05

Price Performance

Historical Comparison
FCO
XLO

About FCO abrdn Global Income Fund Inc.

abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: